PKO Investment Management Joint Stock Co cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,000 shares of the biopharmaceutical company's stock after selling 3,000 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Gilead Sciences were worth $336,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP increased its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter worth $1,789,254,000. Finally, Northern Trust Corp lifted its stake in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer now owns 165,110 shares of the company's stock, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider now owns 120,168 shares in the company, valued at $13,238,908.56. This represents a 2.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,500 shares of company stock worth $5,236,245 over the last quarter. 0.27% of the stock is currently owned by insiders.
Gilead Sciences Stock Performance
Shares of GILD stock opened at $108.00 on Wednesday. The company has a market capitalization of $134.34 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company's 50-day moving average is $105.88 and its 200 day moving average is $102.49.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.
Read Our Latest Stock Report on Gilead Sciences
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
